

RESEARCH

Early Palliative Care and Quality of End-of-Life Care for People With Terminal Cancer, Victoria, 2018–2023: A Retrospective, Population-Based Cohort Study

Chris Schilling^{1,2} | Olivia Wawryk³ | Anna Collins^{3,4}  | Vijaya Sundararajan^{4,5,6} | Brian H. Le⁷  | Jennifer Philip^{2,3}

¹The Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia | ²Centre for Palliative Care, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia | ³The University of Melbourne, Melbourne, Victoria, Australia | ⁴St Vincent's Hospital, Melbourne, Victoria, Australia | ⁵Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia | ⁶St Vincent's Health Australia, Melbourne, Victoria, Australia | ⁷Parkville Integrated Palliative Care Service, The Royal Melbourne Hospital, Melbourne, Victoria, Australia

Correspondence: Chris Schilling (chris.schilling@unimelb.edu.au)

Received: 1 July 2025 | **Revised:** 4 September 2025 | **Accepted:** 8 September 2025

Keywords: cancer | delivery of healthcare | health systems

ABSTRACT

Objectives: To determine how many people who die of cancer in Victoria receive palliative care and early palliative care (more than 3 months before death); to assess the impact of early palliative care on the quality of end-of-life care.

Study Design: Retrospective, population-based cohort study; analysis of linked Victorian Cancer Registry data and routinely collected data for inpatient, non-admitted health service and emergency department care during the 12 months prior to death.

Setting, Participants: Victorian adults who died of cancer during 1 January 2018–31 January 2023.

Main Outcome Measures: Proportions of people who received palliative care (any time) or early palliative care (more than 3 months prior to death); likelihood of quality of end-of-life care measures: dying outside an acute hospital; chemotherapy, two or more emergency department visits, two or more hospital admissions during final 30 days of life; advance care plan at death.

Results: Of 53,305 people who died of cancer (mean age, 74.8 years [standard deviation, 13.0 years]; 29,527 men [55.4%]), palliative care was provided for 38,697 (72.6%); 17,409 people (32.7%) received early palliative care. The most frequent palliative care type was palliative approach to care (Z51.5 code; 33,974 people, 63.7%). The overall proportion of people who received palliative care did not change markedly during 2018–2022; the proportion who received early palliative care declined slightly, from 34.8% (95% confidence interval [CI], 33.6–35.9) to 33.0% (95% CI, 31.7–33.8). People who received early palliative care were more likely than people who received late palliative care to have an advance care plan (adjusted odds ratio [aOR], 1.46; 95% CI, 1.38–1.55) and to die outside hospital (aOR, 2.50; 95% CI, 2.37–2.64); they were less likely to have two or more of emergency department presentations (aOR, 0.75; 95% CI, 0.70–0.81), two or more hospital admissions (aOR, 0.58; 95% CI, 0.55–0.61) or chemotherapy (aOR, 0.51; 95% CI, 0.47–0.55) during their final 30 days of life.

Conclusion: 72.6% of people who died of cancer in Victoria during 2018–2023 had received palliative care, but only 33% had received it early. End-of-life care may be improved by providing palliative care early. The low early palliative care rate, despite the potential for improved outcomes for people who receive it, indicates that action is needed.

Cancer is a leading cause of death around the world [1]. Despite advances in treatment, large proportions of people with cancer experience distressing symptoms and deteriorating health

in the final stages of their illness. Palliative care is consequently an essential component of comprehensive cancer management, aiming to alleviate suffering and to enhance the

Plain Language Summary

The known: Referring people with cancer to palliative care early is recommended to ensure that it effectively alleviates their suffering and enhances the overall quality of life for patients and their families.

The new: Early palliative care was associated with lower levels of poor quality end-of-life care, but only one-third of Victorian adults who died of cancer during 2018–2023 had received it.

The implications: Early palliative care should be provided for all people with terminal cancer, ideally commencing at the time the cancer is diagnosed.

overall quality of life and care for people with cancer and their families [2].

Several systematic reviews, meta-analyses and Australian studies have reported the benefits of integrating palliative care into cancer care early in the course of the illness. The benefits include better symptom management, quality of life and care satisfaction for patients; greater satisfaction with care and readiness to support and care for people with cancer among family members; and lower rates of acute hospital and emergency department presentations at the end of life [3–10]. The American Society of Clinical Oncology recommends referring people with cancer to palliative care, ‘beginning early in the course of the disease, alongside active treatment of their cancer’ [11]. The definition of early palliative care is inconsistent. In some randomised trials it has been defined as care initiated within 2 months of the diagnosis of advanced disease [12, 13]; it has been suggested in Victoria that it should be initiated more than 3 months before the death of the patient [14].

The importance of early initiation of palliative care for people with cancer is recognised, and Australia has one of the best palliative care systems in the world [15], but many people with cancer, including those with poor prognoses, do not receive palliative care according to the evidence for best care.

The aim of our study was to examine palliative care and early palliative care (more than 3 months before death) for people who die of cancer in Victoria. We sought to quantify whether rates of palliative care had improved during 2018–2023, and to identify patient groups for whom access should be improved. To expand the evidence base for effective palliative care in Australia, we assessed associations between receiving early palliative care and a range of standard measures of the quality of end-of-life care.

1 | Methods

We undertook a retrospective, population-based cohort study to examine end-of-life care for all Victorians who died of cancer during 1 January 2018–31 January 2023. We report our study in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [16].

1.1 | Data Sources

We analysed Victorian Cancer Registry data for all adults (18 years or older) who died of cancer-related causes during 1 January 2018–31 January 2023. The data were linked by the Centre for Victorian Data Linkage (Victorian Department of Health and Human Services) to administrative hospital datasets of routinely collected data for inpatient, non-admitted health service and emergency department care during the 12 months prior to death. Health care use data included diagnoses and procedure codes, and health service use in all public and private hospitals and outpatient or community-based care in Victoria [17] (Table S1).

1.2 | Identification of Palliative Care

We used four identifiers of palliative care that were available in the administrative dataset: care type ‘palliative care programme’ or International Classification of Disease, tenth revision (ICD-10) code Z51.5 for inpatient palliative care, episode stream 41 or 1400 for community palliative care and episode stream 1300:1315 or 1600 for outpatient palliative care provided by a hospital-based palliative care consultancy team (Table 1).

1.3 | Outcomes

Two measures were used to categorise palliative care as any, early, late or none:

- Received palliative care (binary outcome): at least one of the palliative care identifiers versus none.

TABLE 1 | Identifiers of palliative care in the administrative datasets used.

| Setting | Palliative care flag | Dataset | Identifiers |
|-------------------------|---|-------------------------------|---------------------------------------|
| Inpatient | Palliative care bed | Admitted episodes (VAED) | Care type ‘palliative care programme’ |
| Inpatient | Palliative approach to care ^a | | ICD-10 code Z51.5 |
| Outpatient | Community palliative care | Non-admitted episodes (VINAH) | Episode stream 41, 1400 |
| Outpatient ^b | Hospital-based palliative care consultancy team | | Episode stream 1300:1315, 1600 |

Abbreviations: ICD, International Classification of Diseases, tenth revision; VAED, Victorian Admitted Episodes Dataset; VINAH, Victorian Integrated Non-Admitted Health.

^aThat is, involves a hospital-based palliative care team consultation. Discussions with key stakeholders and analysis of inpatient and outpatient data suggest an overlap between hospital-based palliative care consultancy team and Z51.5-coded palliative care; all palliative care consultancy team events should have a palliative care Z51.5 code, but not all events with Z51.5 codes will have involved palliative care consultancy teams.

^bOutpatient palliative care consultancy team event may also have Z51.5 codes in the inpatient dataset.

TABLE 2 | Characteristics of 53,305 adults who died of cancer-related causes in Victoria, 1 January 2018–31 January 2023.^a

| Characteristic | 2018 | 2019 | 2020 | 2021 | 2022 | Jan 2023 | 2018–2023 |
|----------------------------------|----------------|----------------|----------------|----------------|--------------|--------------|----------------|
| Number of patients | 10,373 | 10,581 | 10,605 | 10,772 | 9874 | 1100 | 53,305 |
| Age at death (years), mean (SD) | 74.5 (13.1) | 74.8 (13.1) | 74.9 (13.0) | 75.0 (12.9) | 75.0 (12.9) | 75.5 (12.5) | 74.8 (13.0) |
| Age group at death (years) | | | | | | | |
| Under 60 | 1430 (13.8%) | 1436 (13.6%) | 1411 (13.3%) | 1368 (12.7%) | 1196 (12.1%) | 106 (9.6%) | 6947 (13.0%) |
| 60–69 | 2062 (19.9%) | 1976 (18.7%) | 2004 (18.9%) | 2008 (18.6%) | 1769 (17.9%) | 212 (19.3%) | 10,031 (18.8%) |
| 70–79 | 2892 (27.9%) | 3027 (28.6%) | 3028 (28.6%) | 3122 (29.0%) | 2862 (29.0%) | 339 (30.8%) | 15,270 (28.6%) |
| 80–89 | 2940 (28.3%) | 3019 (28.5%) | 2982 (28.1%) | 3110 (28.9%) | 2935 (29.7%) | 305 (27.7%) | 15,291 (28.7%) |
| 90 or older | 1049 (10.1%) | 1123 (10.6%) | 1180 (11.1%) | 1164 (10.8%) | 1112 (11.3%) | 138 (12.5%) | 5766 (10.8%) |
| Sex | | | | | | | |
| Male | 5705 (55.0%) | 5923 (56.0%) | 5932 (55.9%) | 5886 (54.6%) | 5486 (55.6%) | 595 (54.1%) | 29,527 (55.4%) |
| Female | 4668 (45.0%) | 4658 (44.0%) | 4673 (44.1%) | 4885 (45.3%) | 4388 (44.4%) | 505 (45.9%) | 23,777 (44.6%) |
| Missing data | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Birthplace | | | | | | | |
| English-speaking country | 7596 (73.2%) | 7715 (72.9%) | 7639 (72.0%) | 7750 (71.9%) | 7142 (72.3%) | 792 (72.1%) | 38,634 (72.5%) |
| Other | 2777 (26.8%) | 2866 (27.1%) | 2966 (28.0%) | 3022 (28.1%) | 2731 (27.7%) | 307 (27.9%) | 14,669 (27.5%) |
| Missing data | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Indigenous status | | | | | | | |
| Indigenous | 94 (0.9%) | 102 (1.0%) | 122 (1.2%) | 107 (1.0%) | 122 (1.2%) | 11 (1.0%) | 558 (1.0%) |
| Not Indigenous | 10,279 (99.1%) | 10,479 (99.0%) | 10,483 (98.8%) | 10,665 (99.0%) | 9752 (98.8%) | 1089 (99.0%) | 52,747 (99.0%) |
| Tumour stream for cause of death | | | | | | | |
| Breast | 618 (6.0%) | 617 (5.8%) | 624 (5.9%) | 669 (6.2%) | 573 (5.8%) | 69 (6.3%) | 3170 (5.9%) |
| Clinical haematology | 966 (9.3%) | 911 (8.6%) | 959 (9.0%) | 979 (9.1%) | 952 (9.6%) | 100 (9.1%) | 4867 (9.1%) |
| Gastrointestinal, lower | 1340 (12.9%) | 1422 (13.4%) | 1438 (13.6%) | 1413 (13.1%) | 1285 (13.0%) | 124 (11.3%) | 7022 (13.2%) |
| Gastrointestinal, upper | 2064 (19.9%) | 2045 (19.3%) | 2098 (19.8%) | 2163 (20.1%) | 2020 (20.5%) | 220 (20.0%) | 10,610 (19.9%) |
| Genitourinary | 1126 (10.9%) | 1212 (11.5%) | 1263 (11.9%) | 1272 (11.8%) | 1183 (12.0%) | 136 (12.4%) | 6192 (11.6%) |
| Gynaec-oncology | 503 (4.8%) | 532 (5.0%) | 498 (4.7%) | 554 (5.1%) | 481 (4.9%) | 61 (5.5%) | 2629 (4.9%) |

(Continues)

TABLE 2 | (Continued)

| Characteristic | 2018 | 2019 | 2020 | 2021 | 2022 | Jan 2023 | 2018-2023 |
|-------------------------------|--------------|--------------|--------------|--------------|--------------|-------------|----------------|
| Head and neck | 302 (2.9%) | 307 (2.9%) | 317 (3.0%) | 305 (2.8%) | 275 (2.8%) | 27 (2.5%) | 1533 (2.9%) |
| Lung | 2212 (21.3%) | 2264 (21.4%) | 2175 (20.5%) | 2256 (20.9%) | 2095 (21.2%) | 223 (20.3%) | 11,225 (21.1%) |
| Melanoma and skin | 408 (3.9%) | 391 (3.7%) | 407 (3.8%) | 315 (2.9%) | 238 (2.4%) | 36 (3.3%) | 1795 (3.4%) |
| Neuro-oncology | 354 (3.4%) | 392 (3.7%) | 384 (3.6%) | 382 (3.5%) | 360 (3.6%) | 52 (4.7%) | 1924 (3.6%) |
| Sarcoma | 76 (0.7%) | 78 (0.7%) | 72 (0.7%) | 79 (0.7%) | 50 (0.5%) | 15 (1.4%) | 370 (0.7%) |
| Unknown primary | 370 (3.6%) | 388 (3.7%) | 356 (3.4%) | 361 (3.4%) | 350 (3.5%) | 36 (3.3%) | 1861 (3.5%) |
| Missing data | 34 | 22 | 14 | 24 | 12 | 1 | 107 |
| Non-cancer medical conditions | | | | | | | |
| Yes | 5524 (55.4%) | 5661 (55.6%) | 5474 (54.3%) | 5698 (55.4%) | 5061 (53.8%) | 559 (53.5%) | 27,977 (54.9%) |
| No | 4456 (44.6%) | 4518 (44.4%) | 4615 (45.7%) | 4579 (44.6%) | 4341 (46.2%) | 485 (46.5%) | 22,994 (45.1%) |
| Missing data | 393 | 402 | 516 | 495 | 472 | 56 | 2334 |

Abbreviations: ASGS, Australian Statistical Geography Standard; IRSD, Index of Relative Socio-economic Disadvantage; SD, standard deviation.

^a A comprehensive table of characteristics (included any hospital use, marital status, requirement for interpreter, postcode-level socio-economic status and remoteness) is provided in Table S3.

- Received early palliative care: first received palliative care more than 3 months prior to death or within 6 weeks of diagnosis if the person died within 3 months of diagnosis. All other palliative care was defined as late palliative care.

Quality of end-of-life care indicators were based on those used in similar studies [18-20]:

- Site of death: hospital (acute care);
- Site of death: outside a hospital;
- Two or more emergency department presentations during final 30 days of life;
- Two or more hospital admissions during final 30 days of life;
- Acute hospitalisation with combined length of stay exceeding 14 days during the final 30 days of life;
- Inpatient chemotherapy during final 30 days of life; and
- Available advance care plan at death.

We also report the proportions of people with at least one or at least two of these indicators.

1.4 | Statistical Analysis

Using univariable and multivariable logistic regression, we assessed associations between any and early palliative care with quality of end-of-life care indicators and with age group at death, biological sex (male or female), marital status, residential postcode-based remoteness (Australian Statistical Geography Standard) [21] and socio-economic status (Socio-Economic Indexes for Areas [SEIFA] Index of Relative Socio-economic Disadvantage [IRSD] quintile) [22], primary language in country of birth (English or other), requirement for an interpreter in hospital, Indigenous status, private hospital use during the 12 months preceding death, cancer tumour stream (ICD-10 cause of death codes; Table S2), presence of one or more non-cancer medical conditions and year of death. These variables were selected to cover a broad range of socio-demographic, clinical need and geographic factors thought to influence access to palliative care [23]. The multivariable models included all variables in the analysis; we report adjusted odds ratios (aOR) with 95% confidence intervals (CI), and calculated and graphed adjusted predicted proportions of people who received any or early palliative care by tumour stream and year of death using the fitted regression model. Statistical analyses were undertaken in Stata 16.

1.5 | Ethics Statement

The St Vincent's Hospital Human Research Ethics Committee approved the study (LRR 221/20).

2 | Results

The Victorian Cancer Registry recorded 53,305 deaths of adults of cancer-related causes during 1 January 2018–31 January 2023. The mean age at death was 74.8 years (standard deviation,

13.0 years), 29,527 people (55.4%) were male and 14,669 (27.5%) were born in countries where English is not the primary language. The most frequent tumour stream was lung cancer (11,225 people, 21.1%); 27,977 people (54.9%) had at least one medical condition other than cancer (Table 2).

Palliative care was provided for 38,697 people (72.6%); 17,409 (32.7%) received early palliative care. The most frequent palliative care type was palliative approach to care (Z51.5 code; 33,974 people, 63.7%) (Table 3).

Any palliative care was more likely for younger than older people (under 60 years vs. 90 years or older: aOR, 2.88; 95% CI, 2.61–3.17), but early palliative care was less likely (aOR, 0.52; 95% CI, 0.47–0.58). Any palliative care (aOR, 1.07; 95% CI, 1.02–1.12) and early palliative care (aOR, 1.14; 95% CI, 1.08–1.20) were each more likely for women than men (Table 4).

The proportions of people who received any palliative care were largest for gynae-oncology (adjusted predicted rate, 81.4%; 95% CI, 79.8%–83.1%) and sarcoma (80.5%; 95% CI, 76.2%–84.8%) and smallest for clinical haematology (68.5%; 95% CI, 67.1%–69.8%). The proportions of people who received early palliative care were largest for unknown primary cancer type (73.7%; 95% CI, 71.0%–76.3%) and neuro-oncology (52.3%; 95% CI, 49.7%–55.0%) and lowest for clinical haematology (36.1%; 95% CI, 34.4%–37.8%), breast cancer (34.3%; 95% CI, 32.1%–36.4%) and melanoma and skin cancers (30.5%; 95% CI, 27.8%–33.0%) (Figure 1). The overall proportion of people who received palliative care did not change markedly during

2018–2022; the proportion who received early palliative care declined slightly, from 34.8% (95% CI, 33.6%–35.9%) to 33.0% (95% CI, 31.7%–33.8%) (Figure 2).

People who received palliative care were less likely than people who did not to have received chemotherapy during the final 30 days of their lives (aOR, 0.58; 95% CI, 0.54–0.62) and more likely to have had two or more emergency department visits (aOR, 1.49; 95% CI, 1.38–1.61) (Table 5).

People who received early palliative care were less likely than people who received late palliative care to have received chemotherapy (aOR, 0.51; 95% CI, 0.47–0.55), to have had two or more emergency department visits (aOR, 0.75; 95% CI, 0.70–0.81), to have had two or more acute hospital admissions (aOR, 0.58; 95% CI, 0.55–0.61), or to have had acute hospital stays totalling more than 14 days (aOR, 0.69; 95% CI, 0.64–0.73) during the final 30 days of their lives; they were more likely to have advance care plans at death (aOR, 1.46; 95% CI, 1.38–1.55) and to have died outside hospital (aOR, 2.50; 95% CI, 2.37–2.64). At least one indicator of poor end-of-life care was less likely for people who received early palliative care than those who received late palliative care (aOR, 0.47; 95% CI, 0.45–0.49) (Table 5).

3 | Discussion

Fifteen years ago, the landmark Temel study reported the benefits of early palliative care for people with metastatic lung cancer,

TABLE 3 | Palliative care received by 53,305 adults who died of cancer-related causes in Victoria, 1 January 2018–31 January 2023, by care type and year of death.

| Characteristic | 2018 | 2019 | 2020 | 2021 | 2022 | Jan 2023 | 2018–2023 |
|---|--------------|--------------|--------------|--------------|--------------|-------------|----------------|
| Number of patients | 10,373 | 10,581 | 10,605 | 10,772 | 9874 | 1100 | 53,305 |
| Palliative care | 7590 (73.2%) | 7794 (73.7%) | 7665 (72.3%) | 7799 (72.4%) | 7067 (71.6%) | 782 (71.1%) | 38,697 (72.6%) |
| Palliative care type | | | | | | | |
| Admitted to palliative care bed | 3941 (38.0%) | 4229 (40.0%) | 3942 (37.2%) | 4052 (37.6%) | 3720 (37.7%) | 400 (36.4%) | 20,284 (38.1%) |
| Palliative approach to care (Z51.5) | 6786 (65.4%) | 6926 (65.5%) | 6612 (62.3%) | 6812 (63.2%) | 6157 (62.4%) | 681 (61.9%) | 33,974 (63.7%) |
| Community palliative care | 2099 (20.2%) | 2077 (19.6%) | 2435 (23.0%) | 2197 (20.4%) | 1786 (18.1%) | 171 (15.5%) | 10,765 (20.2%) |
| Hospital-based palliative care consultancy team | 2213 (21.3%) | 2288 (21.6%) | 2133 (20.1%) | 1768 (16.4%) | 1810 (18.3%) | 226 (20.5%) | 10,438 (19.6%) |
| Palliative care timing | | | | | | | |
| Early | 3520 (33.9%) | 3531 (33.4%) | 3472 (32.7%) | 3425 (31.8%) | 3125 (31.6%) | 336 (30.5%) | 17,409 (32.7%) |
| Late | 4070 (39.2%) | 4263 (40.3%) | 4193 (39.5%) | 4374 (40.6%) | 3942 (39.9%) | 446 (40.5%) | 21,288 (39.9%) |
| None | 2783 (26.8%) | 2787 (26.3%) | 2940 (27.7%) | 2973 (27.6%) | 2807 (28.4%) | 318 (28.9%) | 14,608 (27.4%) |

TABLE 4 | Associations of palliative care and early palliative care with patient characteristics for 53,305 adults who died of cancer-related causes in Victoria, 1 January 2018–31 January 2023: multivariable analyses.^a

| Characteristic | Adjusted odds ratio (95% CI) | |
|---|---|-----------------------------------|
| | Palliative care versus no palliative care | Early versus late palliative care |
| Age group at death (years) | | |
| Under 60 | 2.88 (2.61–3.17) | 0.52 (0.47–0.58) |
| 60–69 | 2.41 (2.21–2.63) | 0.55 (0.50–0.61) |
| 70–79 | 2.07 (1.91–2.23) | 0.55 (0.50–0.60) |
| 80–89 | 1.62 (1.51–1.75) | 0.76 (0.69–0.83) |
| 90 or older | 1 | 1 |
| Sex (female) | 1.07 (1.02–1.12) | 1.14 (1.08–1.20) |
| Any private hospital use | 0.68 (0.65–0.71) | 0.60 (0.58–0.63) |
| Marital status | | |
| Married | 1 | 1 |
| Widowed | 0.90 (0.85–0.96) | 1.17 (1.10–1.25) |
| Never married | 0.97 (0.90–1.04) | 1.21 (1.13–1.29) |
| Divorced/separated | 1.09 (1.00–1.18) | 1.25 (1.16–1.35) |
| Not stated | 0.82 (0.71–0.95) | 1.36 (1.16–1.60) |
| Born in English-speaking country | 0.89 (0.84–0.95) | 1.03 (0.98–1.10) |
| Interpreter required | 1.40 (1.27–1.55) | 1.02 (0.94–1.12) |
| Indigenous person | 0.87 (0.71–1.08) | 0.93 (0.75–1.14) |
| At least one non-cancer medical condition | 1.03 (0.99–1.08) | 1.09 (1.04–1.14) |
| Socio-economic status (IRSD quintile) | | |
| 1 (least disadvantage) | 1 | 1 |
| 2 | 1.03 (0.97–1.10) | 1.00 (0.95–1.07) |
| 3 | 1.03 (0.96–1.10) | 0.92 (0.86–0.98) |
| 4 | 1.00 (0.94–1.08) | 0.98 (0.92–1.05) |
| 5 (greatest disadvantage) | 1.01 (0.94–1.09) | 0.91 (0.84–0.98) |
| Remoteness (ASGS) | | |
| Major cities | 1 | 1 |
| Inner regional | 1.00 (0.94–1.05) | 1.14 (1.08–1.20) |
| Outer regional | 0.83 (0.76–0.91) | 1.10 (1.00–1.21) |

(Continues)

TABLE 4 | (Continued)


| Characteristic | Adjusted odds ratio (95% CI) | |
|-------------------------|---|-----------------------------------|
| | Palliative care versus no palliative care | Early versus late palliative care |
| Remote/very remote | 1.05 (0.50–2.23) | 0.51 (0.24–1.09) |
| Year of death | | |
| 2018 | 1 | 1 |
| 2019 | 1.06 (0.99–1.14) | 0.99 (0.92–1.05) |
| 2020 | 1.00 (0.94–1.08) | 1.02 (0.95–1.09) |
| 2021 | 1.00 (0.94–1.07) | 0.95 (0.89–1.02) |
| 2022 | 0.96 (0.89–1.04) | 0.92 (0.85–0.99) |
| January 2023 | 0.96 (0.81–1.14) | 0.90 (0.76–1.08) |
| Tumour stream | | |
| Breast | 1 | 1 |
| Clinical haematology | 0.70 (0.62–0.79) | 1.09 (0.96–1.23) |
| Gastrointestinal, lower | 1.03 (0.92–1.16) | 1.54 (1.38–1.73) |
| Gastrointestinal, upper | 1.24 (1.11–1.39) | 1.88 (1.69–2.09) |
| Genitourinary | 0.99 (0.88–1.12) | 1.32 (1.17–1.49) |
| Gynae-oncology | 1.44 (1.25–1.66) | 1.22 (1.07–1.39) |
| Head and neck | 0.93 (0.79–1.09) | 1.20 (1.02–1.42) |
| Lung | 1.13 (1.01–1.26) | 1.94 (1.75–2.16) |
| Melanoma and skin | 1.03 (0.89–1.20) | 0.84 (0.71–0.98) |
| Neuro-oncology | 0.97 (0.83–1.12) | 2.16 (1.87–2.50) |
| Sarcoma | 1.35 (1.01–1.82) | 1.35 (1.04–1.76) |
| Unknown primary | 1.02 (0.88–1.19) | 5.66 (4.78–6.70) |

Abbreviations: ASGS, Australian Statistical Geography Standard [21]; CI, confidence interval; IRSD, Index of Relative Socio-economic Disadvantage [22].

^aAdjusted for all other variables in table. The unadjusted analyses are included in Table S4.

including improved survival [13]. We found that 72.6% of people who died of cancer in Victoria during 2018–2023 had received palliative care; however, only 35% of those who died in 2018 had received early palliative care, and 33% of those who died in 2022. Further, early palliative care was associated with improved end-of-life care; people who received early palliative care were 53% less likely than those who received late palliative care to have an indicator of poor quality of end-of-life care. Specifically, they were 2.5 times as likely to die outside hospital, 25% less likely to have two or more emergency department presentations and 42% less likely to have two or more acute hospital admissions

A. Any palliative care



B. Early palliative care





FIGURE 1 | Adjusted predicted rates (with 95% confidence intervals) of palliative care for 53,305 adults who died of cancer-related causes in Victoria, 1 January 2018–31 January 2023, by tumour stream (derived from the multivariable analysis reported in Table 4).

A. Any palliative care



B. Early palliative care




FIGURE 2 | Adjusted predicted rates (with 95% confidence intervals) of palliative care for 53,305 adults who died of cancer-related causes in Victoria, 1 January 2018–31 January 2023, by year of death (derived from the multivariable analysis reported in Table 4).

TABLE 5 | Association of palliative care and early palliative care with quality of end-of-life care indicators for 53,305 adults who died of cancer-related causes in Victoria, 1 January 2018–31 January 2023: multivariable analyses.^a

| Characteristic | Adjusted odds ratio (95% confidence interval) | | |
|--|---|------------------|-----------------------------------|
| | Palliative care versus no palliative care | | Early versus late palliative care |
| | | | Early versus no palliative care |
| Died in hospital (acute care) | 0.81 (0.77–0.84) | 0.62 (0.59–0.65) | 0.58 (0.55–0.62) |
| Died outside hospital | 0.18 (0.17–0.18) | 2.50 (2.37–2.64) | 0.27 (0.26–0.29) |
| Final 30 days of life | | | |
| Two or more emergency department visits | 1.49 (1.38–1.61) | 0.75 (0.70–0.81) | 1.25 (1.14–1.36) |
| Two or more acute hospital admissions | 0.98 (0.93–1.02) | 0.58 (0.55–0.61) | 0.70 (0.66–0.75) |
| More than 14 days of acute hospital stay | 1.26 (1.19–1.34) | 0.69 (0.64–0.73) | 0.99 (0.92–1.06) |
| Chemotherapy | 0.58 (0.54–0.62) | 0.51 (0.47–0.55) | 0.38 (0.35–0.42) |
| Advance care plan at death | 1.54 (1.44–1.64) | 1.46 (1.38–1.55) | 1.89 (1.76–2.03) |
| At least one indicator | 1.71 (1.64–1.79) | 0.47 (0.45–0.49) | 1.13 (1.07–1.19) |
| At least two indicators | 1.30 (1.25–1.36) | 0.61 (0.58–0.64) | 0.97 (0.92–1.02) |

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio.

^aMultivariable analyses adjusted for all variables in Table 4. The unadjusted analyses are included in Table S5.

during their final month of life and 1.5 times as likely to have an advance care plan. The low early palliative care rate, despite the potential for improved outcomes for people who receive it, indicates that action is needed.

Our analysis of 53,305 cancer deaths in Victoria during 2018–2023 provides a snapshot of the 72.6% of people who received palliative care during this period. We have previously reported that 59% of Victorians who died of cancer during 2000–2010 (29,680 deaths) [24] and 66% of those who died during 2018 (10,245 deaths) [25] had received palliative care. These findings suggest that the provision of palliative care has steadily increased since 2000. However, our new findings suggest that for most people it is confined to end-of-life care, as only about 30% of people received palliative care more than 3 months before they died. Even this definition of early palliative care could be inappropriately conservative for people with known incurable illnesses; the American Society of Clinical Oncology advocates commencing palliative care when the disease is diagnosed [11].

We found that the proportion of people who received early palliative care varied by socio-demographic characteristics and cancer type. The likelihood of receiving early palliative care declined with younger age, reflecting perceptions that palliative care is primarily a last resort for older people on their death beds [26, 27]. People with melanoma or skin or breast, or haematological malignancies were less likely to receive early palliative care than people with most other cancer types. Successful treatment or long term remission is more frequent for people with melanoma or skin or haematological cancers, and the role of palliative care as traditionally understood is uncertain. However, newer models of palliative care, embedded and delivered in parallel with acute and often intensive therapies, can be acceptable for patients and feasible and are associated with benefits for patients and health care teams [28–30]. Including palliative care as part of usual care would reduce the need to identify the best time for referring patients, as all people with diagnosed cancer would receive both holistic acute and palliative care [31].

Our findings regarding the benefits of early palliative care are consistent with those of published meta-analyses and systematic reviews [3–10]. However, randomised controlled trials have yielded mixed results [32, 33], probably reflecting methodological and contextual differences [3]. Trials are typically designed for specific settings and rarely have the statistical power to detect differences in costs or health care use [34]. Observational cohort studies such as ours have the advantage of capturing population-level data in a local context, providing insights directly relevant to Victoria. However, such designs establish associations rather than causal connections, and they can be subject to selection bias, confounding and reverse causality errors. For example, the relationship we found between receiving palliative care and fewer emergency department presentations could indicate that people are referred to palliative care after hospital admissions, rather than palliative care itself leads to changes in hospital use.

3.1 | Limitations

The magnitude of the impact of early palliative care on quality of end-of-life care may vary by the type and amount of palliative

care received. The largest proportion by palliative care type in our study was a palliative approach to care, the code for which (Z51.5) is inconsistently applied [35]. Encouragingly, a recent Australian validation study found that a palliative approach to care was strongly associated with specialist palliative care input [36]. The expanding role of general practitioners in providing early cancer care [37] was not captured by the dataset. Finally, the study period spanned that of the coronavirus disease 2019 (COVID-19) pandemic, which may limit the generalisability of our findings. We found some indication of reduced palliative care being provided in hospitals in 2020 and 2021, offset by increased community palliative care (Table 3), consistent with other reports [38].

3.2 | Conclusion

Our study contributes to the body of evidence for the value of early palliative care for people with cancer. The challenge now is translating this evidence into practice. Central to providing such care is overcoming the uncertainty of clinicians about the optimal timing of referrals to palliative care by establishing clear, objective, easily recognisable transition points in the cancer care trajectory. This work is underway for five advanced cancer types: innovative new models of early palliative care, built on transition points developed by international expert Delphi consensus, are being implemented and evaluated at multiple sites [39]. These and further efforts, including investment and policy that expand both in-person and virtual capacity, will be required to transform the care of all people with advanced cancer, so that early palliative care becomes the norm rather than the exception.

Author Contributions

Chris Schilling: writing original draft and data analysis. **Anna Collins, Vijaya Sundararajan, Brian H. Le and Jennifer Philip:** conceptualisation of the project. **Olivia Wawryk:** data curation and data analysis. **Anna Collins, Olivia Wawryk, Vijaya Sundararajan, Brian H. Le and Jennifer Philip:** review, provide inputs and feedback on the writing.

Acknowledgements

We acknowledge the assistance of our research assistant Florencia Sjaaf (Melbourne School of Population and Global Health, the University of Melbourne).

Funding

Data collection was underpinned by the funding from the Victorian Comprehensive Cancer Centre Alliance.

Disclosure

Not commissioned; externally peer reviewed.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The data for this study will not be shared, as we do not have permission from the participants or ethics approval to do so. The de-identified data

we analysed are not publicly available, but requests to the corresponding author for the data will be considered on a case-by-case basis.

References

1. S. Dattani, V. Samborska, H. Ritchie, and M. Roser, *Cancer* (Our World in Data), <https://ourworldindata.org/cancer>.
2. Cancer Council, *Palliative Care* (Cancer Council, 2023), <https://www.cancer.org.au/cancer-information/treatment/palliative-care>.
3. M. P. Davis, J. S. Temel, T. Balboni, and P. Glare, "A Review of the Trials Which Examine Early Integration of Outpatient and Home Palliative Care for Patients With Serious Illnesses," *Annals of Palliative Medicine* 4 (2015): 99–121.
4. J. J. Fulton, T. W. LeBlanc, T. M. Cutson, et al., "Integrated Outpatient Palliative Care for Patients With Advanced Cancer: A Systematic Review and Meta-Analysis," *Palliative Medicine* 33 (2019): 123–134.
5. J. Gaertner, W. Siemens, J. J. Meerpohl, et al., "Effect of Specialist Palliative Care Services on Quality of Life in Adults With Advanced Incurable Illness in Hospital, Hospice, or Community Settings: Systematic Review and Meta-Analysis," *British Medical Journal* 357 (2017): j2925.
6. M. W. Haun, S. Estel, G. Rücker, et al., "Early Palliative Care for Adults With Advanced Cancer," *Cochrane Database of Systematic Reviews* 6 (2017): CD011129.
7. M. Hoerger, G. R. Wayser, G. Schwing, A. Suzuki, and L. M. Perry, "Impact of Interdisciplinary Outpatient Specialty Palliative Care on Survival and Quality of Life in Adults With Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials," *Annals of Behavioral Medicine* 53 (2018): 674–685.
8. D. Kavalieratos, J. Corbelli, D. Zhang, et al., "Association Between Palliative Care and Patient and Caregiver Outcomes: A Systematic Review and Meta-Analysis," *Journal of the American Medical Association* 316 (2016): 2104–2114.
9. L. K. Rosenwax, B. A. McNamara, K. Murray, R. J. McCabe, S. M. Aoun, and D. C. Currow, "Hospital and Emergency Department Use in the Last Year of Life: A Baseline for Future Modifications to End-of-Life Care," *Medical Journal of Australia* 194 (2011): 570–573.
10. J. Philip, P. Hudson, A. Bostanci, et al., "Metastatic Non-Small Cell Lung Cancer: A Benchmark for Quality End-of-Life Cancer Care?," *Medical Journal of Australia* 202 (2015): 139–143.
11. J. J. Sanders, S. Temin, A. Ghoshal, et al., "Palliative Care for Patients With Cancer: ASCO Guideline Update," *Journal of Clinical Oncology* 42 (2024): 2336–2357.
12. M. A. Bakitas, T. D. Tosteson, Z. Li, et al., "Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial," *Journal of Clinical Oncology* 33 (2015): 1438–1445.
13. J. S. Temel, J. A. Greer, A. Muzikansky, et al., "Early Palliative Care for Patients With Metastatic Non-Small-Cell Lung Cancer," *New England Journal of Medicine* 363 (2010): 733–742.
14. Victorian Integrated Cancer Services, *Palliative Care and Advance Care Planning: Current Practices in Victorian Cancer Services* (Victorian Integrated Cancer Services, n.d.), <https://www.vics.org.au/projects/palliative-care-and-advance-care-planning-current-practices-in-victorian-cancer-services>.
15. Economist Intelligence Unit, *The Quality of Death. Ranking End-of-Life Care Across the World* (Lien Foundation, 2010), https://lienfoundation.org/wp-content/uploads/2024/11/qod_index_2010.pdf.
16. E. von Elm, D. G. Altman, M. Egger, et al., "The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies," *Lancet* 370 (2007): 1453–1457.
17. Department of Health (Victoria), "Data Collections," 2025, <https://www.health.vic.gov.au/data-reporting/data-collections>.
18. C. C. Earle, E. R. Park, B. Lai, J. C. Weeks, J. Z. Ayanian, and S. Block, "Identifying Potential Indicators of the Quality of End-Of-Life Cancer Care From Administrative Data," *Journal of Clinical Oncology* 21 (2003): 1133–1138.
19. E. Grunfeld, L. Lethbridge, R. Dewar, et al., "Towards Using Administrative Databases to Measure Population-Based Indicators of Quality of End-Of-Life Care: Testing the Methodology," *Palliative Medicine* 20 (2006): 769–777.
20. E. Grunfeld, R. Urquhart, E. Mykhalovskiy, et al., "Toward Population-Based Indicators of Quality End-of-Life Care," *Cancer* 112 (2008): 2301–2308.
21. Australian Bureau of Statistics, "Remoteness Areas. Australian Statistical Geography Standard (ASGS) Edition 3; July 2021–June 2026," 2023, <https://www.abs.gov.au/statistics/standards/australian-statistical-geography-standard-asgs-edition-3/jul2021-jun2026/remoteness-structure/remoteness-areas>.
22. Australian Bureau of Statistics, "Index of Relative Socio-Economic Disadvantage (IRSD)," in *Socio-Economic Indexes for Areas (SEIFA), Australia*; 2021, 2023, <https://www.abs.gov.au/statistics/people/people-and-communities/socio-economic-indexes-areas-seifa-australia/latest-release#index-of-relative-socio-economic-disadvantage-irsd->.
23. G. Sitima, C. Galhardo-Branco, and P. Reis-Pina, "Equity of Access to Palliative Care: A Scoping Review," *International Journal for Equity in Health* 23 (2024): 248.
24. A. Collins, V. Sundararajan, J. Burchell, et al., "Transition Points for the Routine Integration of Palliative Care in Patients With Advanced Cancer," *Journal of Pain and Symptom Management* 56 (2018): 185–194.
25. J. Philip, A. Collins, O. Warwyk, V. Sundararajan, and B. Le, "Is the Use of Palliative Care Services Increasing? A Comparison of Current Versus Historical Palliative Care Access Using Health Service Datasets for Patients With Cancer," *Palliative Medicine* 36 (2022): 1426–1431.
26. A. Collins, S. A. McLachlan, and J. Philip, "Initial Perceptions of Palliative Care: An Exploratory Qualitative Study of Patients With Advanced Cancer and Their Family Caregivers," *Palliative Medicine* 31 (2017): 825–832.
27. C. Johnson, A. Girgis, C. Paul, D. C. Currow, J. Adams, and S. Aranda, "Australian Palliative Care Providers' Perceptions and Experiences of the Barriers and Facilitators to Palliative Care Provision," *Support Care Cancer* 19 (2011): 343–351.
28. A. El-Jawahri, T. W. LeBlanc, A. Kavanaugh, et al., "Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial," *JAMA Oncology* 7 (2021): 238–245.
29. A. El-Jawahri, T. W. LeBlanc, A. Kavanaugh, et al., "Multi-Site Randomized Trial of Inpatient Palliative Care for Hospitalized Patients Undergoing Hematopoietic Stem Cell Transplantation [Abstract: 85th Annual American Society of Hematology Meeting, San Diego, 6–15 Dec 2023]," *Blood* 142, no. S1 (2023): 913.
30. C. S. Weisse, K. Melekis, A. Cheng, A. K. Konda, and A. Major, "Mixed-Methods Study of End-Of-Life Experiences of Patients With Hematologic Malignancies in Social Hospice Residential Home Care Settings," *JCO Oncology Practice* 20 (2024): 779–786.
31. T. W. LeBlanc, E. J. Roeland, and A. El-Jawahri, "Early Palliative Care for Patients With Hematologic Malignancies: Is It Really So Difficult to Achieve?," *Current Hematologic Malignancy Reports* 12 (2017): 300–308.
32. C. Zimmermann, N. Swami, M. Krzyzanowska, et al., "Early Palliative Care for Patients With Advanced Cancer: A Cluster-Randomised Controlled Trial," *Lancet* 383 (2014): 1721–1730.

33. L. R. Mileshkin, J. Yoong, R. Eggins, et al., “PEARL: A Randomised Phase 3 Trial of Palliative Care Early in Advanced Lung Cancers [Abstract: 2022 American Society of Clinical Oncology Meeting, Chicago, 3–7 June 2022],” *Journal of Clinical Oncology* 40, no. 16S (2022): 12020.

34. M. Jacobson, P. May, and R. S. Morrison, “Improving Care of People With Serious Medical Illness: An Economic Research Agenda for Palliative Care,” *JAMA Health Forum* 3 (2022): e214464.

35. J. B. Cassel, “What Does “Palliative Care” Represent in Research Using Secondary Data?,” *Journal of Pain and Symptom Management* 68 (2024): 421–428.

36. J. M. Stubbs, H. Assareh, H. M. Achat, S. Greenaway, and P. Muruganantham, “Verification of Administrative Data to Measure Palliative Care at Terminal Hospital Stays,” *Health Information Management* 52 (2023): 28–36.

37. G. Rubin, A. Berendsen, S. M. Crawford, et al., “The Expanding Role of Primary Care in Cancer Control,” *Lancet Oncology* 16 (2015): 1231–1272.

38. M. O’Connor, “Home-Based Palliative Care Services After COVID-19 [Letter],” *Medical Journal of Australia* 218 (2023): 492.

39. J. Philip, R. Le Gautier, A. Collins, et al., “Care Plus Study: A Multi-Site Implementation of Early Palliative Care in Routine Practice to Improve Health Outcomes and Reduce Hospital Admissions for People With Advanced Cancer: A Study Protocol,” *BMC Health Services Research* 21 (2021): 513.

Supporting Information

Additional supporting information can be found online in the Supporting Information section. **Data S1:** mja270128-sup-0001-Supinfo.pdf.